Literature DB >> 31867770

Use of peripheral plasma aldosterone concentration and response to ACTH during simultaneous bilateral adrenal veins sampling to predict the source of aldosterone secretion in primary aldosteronism.

Matthieu St-Jean1, Isabelle Bourdeau1, Éric Therasse2, André Lacroix1.   

Abstract

CONTEXT: Previous studies suggested that plasma aldosterone (PAC) response to ACTH stimulation could predict the subtypes of primary aldosteronism (PA) and avoid adrenal venous sampling (AVS).
OBJECTIVE: Assess the usefulness of peripheral (P) PAC response to ACTH stimulation during AVS to identify the source of aldosterone in patients with PA.
METHODS: Two hundred and fifteen patients were assigned to four different lateralization ratio (LR) groups based on different combinations of basal (≥ or <2) and post-ACTH LR (≥ or <4). The P vein parameters analysed included as follows: mean basal PAC, maximal PAC (PACmax ), and PAC/C ratio (PACmax /C), PAC absolute increase, PAC relative increase following ACTH bolus (250 mcg IV) and maximal variation of PAC/C ratio between post-ACTH and basal measures.
RESULTS: Mean basal PAC was significantly higher in group 1 (basal LR > 2 and post-ACTH > 4) than in group 2 (basal LR > 2, post-ACTH < 4) or group 4 (basal LR < 2 post-ACTH < 4) (P < .001). PACmax , PACmax /C and PAC absolute increase following ACTH were higher in group 1 than the others (P < .017). Using receiver operating characteristic (ROC) curves analysis of groups 1 and 4, best AUC were obtained with mean basal PAC (AUC: 0.757 95% IC: 0.653-0.861), PACmax (AUC: 0.753 95% IC: 0.646-0.860) and PACmax /C (AUC: 0.750 95% IC: 0.646-0.853).
CONCLUSION: P mean basal PAC and PACmax and PACmax /C are higher in basal and ACTH lateralized PA than in other groups. Peripheral PAC cut-off values fail to adequately distinguish all groups and cannot replace the requirement to conduct AVS.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  ACTH stimulation; aldosterone; bilateral adrenal veins sampling; primary aldosteronism

Year:  2019        PMID: 31867770     DOI: 10.1111/cen.14137

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection.

Authors:  Nicholas Yozamp; Gregory L Hundemer; Marwan Moussa; Jonathan Underhill; Tali Fudim; Barry Sacks; Anand Vaidya
Journal:  Hypertension       Date:  2020-12-07       Impact factor: 10.190

Review 2.  Adrenocorticotropic Hormone-Stimulated Adrenal Venous Sampling Underestimates Surgically Curable Primary Aldosteronism: A Retrospective Cohort Study and Review of Contemporary Studies.

Authors:  Nicholas Yozamp; Gregory L Hundemer; Marwan Moussa; Jonathan Underhill; Tali Fudim; Barry Sacks; Anand Vaidya
Journal:  Hypertension       Date:  2021-05-17       Impact factor: 9.897

3.  Variability of Aldosterone Measurements During Adrenal Venous Sampling for Primary Aldosteronism.

Authors:  Nicholas Yozamp; Gregory L Hundemer; Marwan Moussa; Johnathan Underhill; Tali Fudim; Barry Sacks; Anand Vaidya
Journal:  Am J Hypertens       Date:  2021-02-18       Impact factor: 3.080

4.  Re-Assessment of the Oral Salt Loading Test Using a New Chemiluminescent Enzyme Immunoassay Based on a Two-Step Sandwich Method to Measure 24-Hour Urine Aldosterone Excretion.

Authors:  Yoshinori Ozeki; Mizuki Kinoshita; Shotaro Miyamoto; Yuichi Yoshida; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Kengo Kambara; Hirotaka Shibata
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-21       Impact factor: 5.555

5.  Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations.

Authors:  Yoshinori Ozeki; Yukie Tanimura; Satoshi Nagai; Takuya Nomura; Mizuki Kinoshita; Kanako Shibuta; Naoki Matsuda; Shotaro Miyamoto; Yuichi Yoshida; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Kengo Kambara; Hirotaka Shibata
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.